세포치료 및 유전자 치료 시장에 대해 조사했으며, 역동적이고 급속히 진화하는 세포치료 및 유전자 치료 시장에 대한 종합적인 시각을 제공합니다. 2021년 1분기부터 2024년 1분기까지 시행된 중요한 거래에 초점을 맞추고, 이 급성장 분야를 형성하는 동향을 이해하고, 활용하고자 하는 기업 및 이해관계자에게 귀중한 인사이트를 제공합니다.
목차
제1장 주요 요약
제2장 벤처캐피털과 민간 자금조달
유동적인 VC/민간 자금조달
제3장 전략적 투자
세포치료 및 유전자 치료에 대한 전략적 투자
제4장 IPO, FPO, SPAC
북미에서는 IPO, FPO, SPAC별 매출이 대부분을 차지한다.
제5장 합병과 인수(M&A)
평균 가치의 하락에도 불구하고 M&A 건수는 증가
제6장 기술/조사/전략적 협업
CGT 시장에서는 다양한 협업이 보인다.
제7장 라이선싱
세포치료 및 유전자 치료 시장에서 라이선싱의 안정 레벨
제8장 제조와 공급망
CGT에서 제조 및 공급망 관리 활동의 대폭적인 성장
제9장 유통과 공동 마케팅
CGT 판매 및 공동 마케팅 계약의 개요
제10장 기타 - JV, 재편, 해산, 스핀오프
세포치료 및 유전자 치료에 영향을 미치는 기타 종류의 거래 보기
KSA
영문 목차
영문목차
"Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024" is published in two installments, the first in Q2 2024 and the second in Q4 2024. Customers who purchase the report will receive both installments.
Kalorama Information's "Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024" offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and stakeholders looking to understand and leverage the trends shaping this burgeoning field.
No report published by a major market research publisher has tackled the cell and gene therapy dealmaking space more comprehensively. With cell and gene therapy is becoming a highly competitive marketplace, over a thousand companies are specifically referenced in this report.
Why This Report?
With over 1,500 companies actively involved in the cell and gene therapy space, understanding the trends and competitive landscape is crucial for strategic planning. "Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024" provides the essential market analysis needed to navigate and capitalize on the opportunities within this fast-growing industry.
Report Highlights:
Quarterly Funding Trends (Q1 2021-Q1 2024): Graphical representation of funding amounts, showcasing investment influx in cell and gene therapy.
Deal Types: Comprehensive categorization of 2000+ deals, including venture capital, private investments, mergers, acquisitions, strategic collaborations, licensing, manufacturing/ supply, and distribution/ co-marketing.
Top Deal-Makers: Identification of the most active companies by deal type and overall deal activity.
Regional Deal Breakdown: Percentage analysis of deal-making activities across different regions.
Who Should Buy This Report
Understanding the volumes of deals that have been made, who is making which type and how many, and the deals' details, is critical to finding how to take advantage of the opportunities in one of the fastest-growing markets.
Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 is designed to provide companies entering or already in this market with knowledge of the trends in deals that will shape future growth and competition.
The following is just some of the information in this report:
Quarterly Funding Amounts Q1 2021- Q1 2024 by Type and Region
Specific details of 2000+ CGT Deals
Venture Capital/Private Funding Round Amounts, By Quarter
Chronological Trends Presented in Multiple Categories (VC, M&A, Other Areas)
Deals by Type - Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation
Most Active Deal-Making Companies, by Type of Deal (Acquisition/Merger/ Strategic Investment, Overall Deals, Collaborations)
Regional Breakdown of Dealmaking [North America, Europe, APAC, Rest of World] (%)
Methodology
The report's insights are derived from a blend of primary and secondary research, including interviews with industry professionals, comprehensive literature reviews, and analysis of company and government reports.
Table of Contents
Chapter 1: Executive Summary
Introduction
$35 Billion in Investment in 2023
Figure 1-1: Total Deals per Month, April 2021-April 2024 (count)
Figure 1-2: Total Deals per Month, by Type [VC/ Private, IPO/FPO/SPAC; and All Other Deals], April 2021-April 2024 (count)
Quarterly Funding Amounts
Table 1-1: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], Q1 2024 (in millions $)
Table 1-2: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2023 (in millions $)
Table 1-3: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2022 (in millions $)
Table 1-4: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2021 (in millions $)
Table 1-5: Total Quarterly Funding, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2021-Q1 2024 (in millions $)
Figure 1-3: Total Quarterly Funding, Q1 2021- Q1 2024 (in millions $)
Figure 1-4: Total Quarterly Funding, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], Q1 2021-Q1 2024 (in millions $)
Quarterly Funding Category Shares, Q1 2021 Through Q1 2024
Table 1-6: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2023 (%)
Table 1-7: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2022
Table 1-8: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2021 (%)
Table 1-9: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2021-Q1 2024 (%)
Figure 1-5: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], Q1 2021-Q1 2024 (%)
Figure 1-6: January-April 2024 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-7: 2023 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-8: 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-9: 2021 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Quarterly Deal Counts by Category, Q1 2021 - Q1 2024
Table 1-11: Quarterly Count of Deals, By 2023 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal] (total number) (%)
Table 1-12: Quarterly Count of Deals, by 2022 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture] (total number) (%)
Table 1-13: Quarterly Count of Deals, by 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture] (total number) (%)
Table 1-14: Yearly Shares of Number of Deals, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture], 2021-2024 partial (%)
Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/ Co-Marketing Highlight Activity in Cell and Gene Therapy
Figure 1-10a: Yearly Shares of Number of Deals, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain], 2021-2024 partial (%)
Figure 1-10b: Yearly Shares of Number of Deals, By Category [Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture], 2021-2024 partial (%)
Figure 1-11: Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain], Q1 2021-Q1 2024 (Total number)
A Look at Less Frequent CGT Deal Types
Figure 1-12: Lower Frequency Deal Types, by Quarter, by Category [Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture], Q1 2021-Q1 2024 (total number)
Figure 1-13: Merger/Acquisition Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
Figure 1-14: Venture Capital/Private Funding Round Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
Figure 1-15: IPO/FPO Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
Figure 1-16: SPAC Portion Amount, by Year, 2021-2023 (in millions $)
Most Active Companies
Table 1-15: Most Active Companies in CGT Deals, Collaborations, Overall 2021-April 2024
Figure 1-17: Most Active Companies in CGT Deals, Collaborations, Overall 2021-April 2024
Chapter 2: Venture Capital & Private Funding
VC/Private Funding in Flux
Figure 2-1: Total Number of Private Funding/VC Rounds, by Month, Jan 2021-April 2024 (count)
Figure 2-2: Average Private Funding/VC Round Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
Table 2-1: Regional Venture Capital/Private Funding, by Region [North America, Europe, APAC, Rest of World], by Quarter Q1 2021-Q1 2024 (in millions $) (%)
Figure 2-3: Quarterly Venture Capital/Private Total Funding, by Region [North America, Europe, APAC, Rest of World], Q1 2021-Q1 2024 (in millions $)
Table 2-2: Regional Venture Capital/Private Funding Shares, by Region [North America, Europe, APAC, Rest of World], by Quarter Q1 2021-Q1 2024 (%)
Figure 2-4: Regional Venture Capital/Private Funding Shares, by Region [North America, Europe, APAC, Rest of World], by Quarter, Q1 2021-Q1 2024, (%)
Figure 2-5: Venture Capital/Private Funding Round Amounts, By Quarter, Q1 2021-Q1 2024 (in millions $)
Figure 2-6: Scaled Venture Capital/Private Funding Round Amounts, By Quarter, Q1 2021-Q1 2024 (in millions $)
